Tessa Romero
Stock Analyst at JP Morgan
(4.19)
# 524
Out of 4,761 analysts
56
Total ratings
46.34%
Success rate
19.55%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tessa Romero
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UPB Upstream Bio | Initiates: Overweight | $38 | $7.98 | +376.19% | 1 | Nov 5, 2024 | |
| NMRA Neumora Therapeutics | Downgrades: Neutral | $18 → $15 | $1.80 | +733.33% | 4 | Nov 5, 2024 | |
| DYN Dyne Therapeutics | Downgrades: Neutral | $43 → $35 | $14.01 | +149.82% | 4 | Oct 24, 2024 | |
| MCRB Seres Therapeutics | Downgrades: Underweight | n/a | $0.80 | - | 2 | Oct 24, 2024 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $18 → $31 | $37.70 | -17.77% | 5 | Oct 14, 2024 | |
| BHVN Biohaven | Maintains: Overweight | $55 → $68 | $36.91 | +84.23% | 5 | Oct 3, 2024 | |
| CYTK Cytokinetics | Maintains: Overweight | $65 → $71 | $50.26 | +41.27% | 4 | Sep 5, 2024 | |
| EYPT EyePoint Pharmaceuticals | Maintains: Overweight | $32 → $29 | $6.15 | +371.54% | 3 | Aug 13, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Overweight | $30 → $31 | $27.07 | +14.52% | 8 | Aug 12, 2024 | |
| AGIO Agios Pharmaceuticals | Reinstates: Neutral | $46 | $35.22 | +30.61% | 6 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $25 | $19.95 | +25.31% | 6 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $3.89 | +414.14% | 1 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $7 | $5.72 | +22.38% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $55 | $39.73 | +38.43% | 2 | Apr 25, 2023 |
Upstream Bio
Nov 5, 2024
Initiates: Overweight
Price Target: $38
Current: $7.98
Upside: +376.19%
Neumora Therapeutics
Nov 5, 2024
Downgrades: Neutral
Price Target: $18 → $15
Current: $1.80
Upside: +733.33%
Dyne Therapeutics
Oct 24, 2024
Downgrades: Neutral
Price Target: $43 → $35
Current: $14.01
Upside: +149.82%
Seres Therapeutics
Oct 24, 2024
Downgrades: Underweight
Price Target: n/a
Current: $0.80
Upside: -
Scholar Rock Holding
Oct 14, 2024
Maintains: Overweight
Price Target: $18 → $31
Current: $37.70
Upside: -17.77%
Biohaven
Oct 3, 2024
Maintains: Overweight
Price Target: $55 → $68
Current: $36.91
Upside: +84.23%
Cytokinetics
Sep 5, 2024
Maintains: Overweight
Price Target: $65 → $71
Current: $50.26
Upside: +41.27%
EyePoint Pharmaceuticals
Aug 13, 2024
Maintains: Overweight
Price Target: $32 → $29
Current: $6.15
Upside: +371.54%
Edgewise Therapeutics
Aug 12, 2024
Maintains: Overweight
Price Target: $30 → $31
Current: $27.07
Upside: +14.52%
Agios Pharmaceuticals
Jun 13, 2024
Reinstates: Neutral
Price Target: $46
Current: $35.22
Upside: +30.61%
Mar 25, 2024
Maintains: Overweight
Price Target: $29 → $25
Current: $19.95
Upside: +25.31%
Nov 28, 2023
Initiates: Overweight
Price Target: $20
Current: $3.89
Upside: +414.14%
Aug 22, 2023
Maintains: Underweight
Price Target: $8 → $7
Current: $5.72
Upside: +22.38%
Apr 25, 2023
Maintains: Overweight
Price Target: $54 → $55
Current: $39.73
Upside: +38.43%